SC
RCUS icon

SummitTX Capital’s Arcus Biosciences RCUS Stock Holding History

SummitTX Capital’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.56M Buy
50,463
+16,244
+47% +$401K 0.04% 376
2026
Q1 		$739K Buy
34,219
+5,076
+17% +$110K 0.02% 505
2025
Q4 		$694K Buy
29,143
+11,589
+66% +$236K 0.02% 478
2025
Q3 		$239K Sell
17,554
-11,070
-39% -$115K 0.01% 675
2025
Q2 		$233K Sell
28,624
-82,266
-74% -$703K 0.01% 666
2025
Q1 		$870K Buy
+110,890
New +$1.29M 0.04% 434

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

SummitTX Capital's RCUS Position: Q2 2026 in Review

SummitTX Capital increased its Arcus Biosciences (RCUS) stake by 47% in Q2 2026, buying an estimated $401K and bringing the position to 50,463 shares worth $1.56M. The position accounts for 0.04% of the portfolio, ranked #376.

SummitTX Capital first reported a position in RCUS in Q1 2025 and has held it in 6 quarters since. 232 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • SummitTX Capital held 50,463 shares of Arcus Biosciences worth $1.56M as of Q2 2026.
  • SummitTX Capital bought 16,244 Arcus Biosciences shares in Q2 2026, an estimated $401K.
  • Arcus Biosciences made up 0.04% of SummitTX Capital's portfolio in Q2 2026, its #376 holding.
  • SummitTX Capital first reported a position in Arcus Biosciences in Q1 2025 and has held it in 6 quarters since.
  • 232 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.